Design, Synthesis and Biological Evaluation of Novel (E)-Α-benzylsulfonyl Chalcone Derivatives As Potential BRAF Inhibitors.

Qing-Shan Li,Cui-Yun Li,Xiang Lu,Hui Zhang,Hai-Liang Zhu

DOI: https://doi.org/10.1016/j.ejmech.2012.02.007

IF: 7.088

2012-01-01

European Journal of Medicinal Chemistry

Abstract:Activating mutations in the BRAF serine/threonine kinase are found in more than 70% of human melanomas, >90% of which are BRAF(V600E). It provides new therapeutic opportunities in malignant melanoma. In silico and in vitro screening of our compound collection has identified Hit 2 as BRAF(V600E) inhibitor. Based on its structure, a series of novel (E)-alpha-benzylsulfonyl chalcone derivatives (13-40) were designed and synthesized. Compound 38 exhibited the most potent inhibitory activity with an IC50 value of 0.17 mu M for BRAF(V600E) and GI(50) value of 0.52 mu M for mutant BRAF-dependent cells. The results of cell based pERK activity and cellular selectivity suggested that those compounds could selectively inhibit proliferation of mutant BRAF-dependent melanoma cell line through inhibition of oncogenic BRAF. (C) 2012 Elsevier Masson SAS. All rights reserved.